Skip to main content

Recent Posts

News

Speeding the Diagnosis of Rare Genetic Disorders with the Help of Artificial Intelligence

Millions of children around the world are born each year with severe genetic disorders. Many of these are Mendelian disorders, which are rare genetic conditions caused by mutations in a single gene. But pinpointing the specific gene responsible for a disorder to get a clear diagnosis for an individual can be labor-intensive, and reanalysis of undiagnosed cases is also difficult. As a result, only about 30% of people with a rare genetic disorder get a definitive diagnosis, and on average, it takes 6 years from symptom onset to diagnosis.

Progress is needed to get accurate diagnoses to individuals and families more often and faster, and to create more efficient ways to update genetic diagnoses as new discoveries are made. As an important step in this direction, a team funded in part by NIH has developed a new artificial intelligence (AI) system called AI-MARRVEL (AI-Model organism Aggregated Resources for Rare Variant ExpLoration).

News

AI Tool Using Single-Cell Data Has Promise for Optimally Matching Cancer Drugs to Patients

Precision oncology, in which doctors choose cancer treatment options based on the underlying molecular or genetic signature of individual tumors, has come a long way. The Food and Drug Administration has approved a growing number of tests that look for specific genetic changes that drive cancer growth to match patients to targeted treatments. The NCI-MATCH trial, supported by the National Cancer Institute, in which participants with advanced or rare cancer had their tumors sequenced in search of genetic changes that matched them to a treatment, has also suggested benefits for guiding treatment through genetic sequencing. But there remains a need to better predict treatment responses for people with cancer.

A promising approach is to analyze a tumor’s RNA in addition to its DNA. The idea is to not only better understand underlying genetic changes, but also learn how those changes impact gene activity as measured by RNA sequencing data. A recent study introduces an artificial intelligence (AI)-driven tool, dubbed PERCEPTION (PERsonalized single-Cell Expression-based Planning for Treatments in ONcology), developed by an NIH-led team to do just this. This proof-of-concept study, published in Nature Cancer, shows that it’s possible to fine-tune predictions of a patient’s treatment responses from bulk RNA data by zeroing in on what’s happening inside single cells.

News

Machine Learning Study Offers Clues to Why Some People Have Rheumatoid Arthritis Pain Without Inflammation

About 1.5 million adults in the U.S. are living with rheumatoid arthritis (RA), an autoimmune disease in which the immune system attacks joint tissue, causing inflammation, swelling, and pain. Treatments often do a good job fighting inflammation to slow or even stop joint damage and ease pain. But this doesn’t work for everyone. Many people with RA don’t find pain relief, even with the strongest anti-inflammatory, disease-modifying therapies now available.

Why is that? A new study supported in part by NIH and reported in Science Translational Medicine has an intriguing answer. The findings suggest that in some people with RA, the joint lining may direct the growth of pain-sensing neurons to cause pain in the absence of inflammation. This discovery, made possible with the help of machine learning, suggests potential new ways to treat this painful disease.